Evidence from knockdown experiments supports the therapeutic potential of RPS6 targeting in various cancer cells including breast cancer, cervical carcinoma, head and neck cancer, gastric cancer, glioblastoma, HCC, hematopoietic cancer, lung cancer, melanoma, ovarian cancer, and sarcoma (Figure 5). This evidence concerns the gene RPS6 and ovarian cancer.